• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥美拉唑在人细胞色素P450酶作用下的立体选择性代谢

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.

作者信息

Abelö A, Andersson T B, Antonsson M, Naudot A K, Skånberg I, Weidolf L

机构信息

AstraZeneca R&D Mölndal, Mölndal, Sweden.

出版信息

Drug Metab Dispos. 2000 Aug;28(8):966-72.

PMID:10901708
Abstract

This study demonstrates the stereoselective metabolism of the optical isomers of omeprazole in human liver microsomes. The intrinsic clearance (CL(int)) of the formation of the hydroxy metabolite from S-omeprazole was 10-fold lower than that from R-omeprazole. However, the CL(int) value for the sulfone and 5-O-desmethyl metabolites from S-omeprazole was higher than that from R-omeprazole. The sum of the CL(int) of the formation of all three metabolites was 14.6 and 42.5 microl/min/mg protein for S- and R-omeprazole, respectively. This indicates that S-omeprazole is cleared more slowly than R-omeprazole in vivo. The stereoselective metabolism of the optical isomers is mediated primarily by cytochrome P450 (CYP) 2C19, as indicated by studies using cDNA-expressed enzymes. This is the result of a considerably higher CL(int) of the 5-hydroxy metabolite formation for R- than for S-omeprazole. For S-omeprazole, CYP2C19 is more important for 5-O-desmethyl formation than for 5-hydroxylation. Predictions of the CL(int) using data from cDNA-expressed enzymes suggest that CYP2C19 is responsible for 40 and 87% of the total CL(int) of S- and R-omeprazole, respectively, in human liver microsomes. According to experiments using cDNA-expressed enzymes, the sulfoxidation of both optical isomers is metabolized by a single isoform, CYP3A4. The CL(int) of the sulfone formation by CYP3A4 is 10-fold higher for S-omeprazole than for R-omeprazole, which may contribute to their stereoselective disposition. The results of this study show that both CYP2C19 and CYP3A4 exhibit a stereoselective metabolism of omeprazole. CYP2C19 favors 5-hydroxylation of the pyridine group of R-omeprazole, whereas the same enzyme mainly 5-O-demethylates S-omeprazole in the benzimidazole group. Sulfoxidation mediated by CYP3A4 highly favors the S-form.

摘要

本研究证明了奥美拉唑光学异构体在人肝微粒体中的立体选择性代谢。S-奥美拉唑形成羟基代谢物的内在清除率(CL(int))比R-奥美拉唑低10倍。然而,S-奥美拉唑形成砜和5-O-去甲基代谢物的CL(int)值高于R-奥美拉唑。S-和R-奥美拉唑形成所有三种代谢物的CL(int)总和分别为14.6和42.5微升/分钟/毫克蛋白。这表明S-奥美拉唑在体内的清除速度比R-奥美拉唑慢。光学异构体的立体选择性代谢主要由细胞色素P450(CYP)2C19介导,使用cDNA表达酶的研究表明了这一点。这是R-奥美拉唑形成5-羟基代谢物的CL(int)比S-奥美拉唑高得多的结果。对于S-奥美拉唑,CYP2C19对5-O-去甲基形成比对5-羟基化更重要。使用cDNA表达酶的数据预测CL(int)表明,在人肝微粒体中,CYP2C19分别占S-和R-奥美拉唑总CL(int)的40%和87%。根据使用cDNA表达酶的实验,两种光学异构体的亚砜化均由单一同工型CYP3A4代谢。CYP3A4形成砜的CL(int)对于S-奥美拉唑比R-奥美拉唑高10倍,这可能有助于它们的立体选择性处置。本研究结果表明,CYP2C19和CYP3A4均表现出奥美拉唑的立体选择性代谢。CYP2C19有利于R-奥美拉唑吡啶基团的5-羟基化,而同一酶主要使S-奥美拉唑在苯并咪唑基团中发生5-O-去甲基化。CYP3A4介导的亚砜化高度有利于S-型。

相似文献

1
Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.奥美拉唑在人细胞色素P450酶作用下的立体选择性代谢
Drug Metab Dispos. 2000 Aug;28(8):966-72.
2
Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.兰索拉唑在人肝细胞色素P450酶中的立体选择性代谢。
Drug Metab Dispos. 2003 Oct;31(10):1227-34. doi: 10.1124/dmd.31.10.1227.
3
Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole.人肝脏CYP酶对一种取代苯并咪唑的立体选择性代谢。
Drug Metab Dispos. 2000 Jan;28(1):58-64.
4
Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.CYP3A4和CYP2C19在人肝微粒体对兰索拉唑的立体选择性代谢中的作用。
Eur J Clin Pharmacol. 2001 Dec;57(10):709-15. doi: 10.1007/s002280100374.
5
Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.细胞色素P450 2C19和3A4在人肝微粒体氧化奥美拉唑过程中的不同贡献:个体人样本中这两种形式含量的影响
J Pharmacol Exp Ther. 1997 Nov;283(2):434-42.
6
Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.参与格列本脲和兰索拉唑代谢的人细胞色素P450同工酶的鉴定及其相对贡献:基于体外底物消失率的方法评估
Xenobiotica. 2004 May;34(5):415-27. doi: 10.1080/00498250410001685728.
7
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.人肝细胞色素P450在体外与胃质子泵抑制剂LY307640的相互作用。
Pharmacogenetics. 1996 Feb;6(1):81-91. doi: 10.1097/00008571-199602000-00007.
8
Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.重组细胞色素P450酶实验表明,人CYP2C19是主要的奥美拉唑5-羟化酶。
Drug Metab Dispos. 1996 Oct;24(10):1081-7.
9
Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.奥美拉唑在人肝微粒体中的氧化代谢:与S-美芬妥因4'-羟化作用的共分离
J Pharmacol Exp Ther. 1993 Jul;266(1):52-9.
10
Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone.通过定量测定5-羟基奥美拉唑和奥美拉唑砜来探究中国肝微粒体中CYP2C19和CYP3A4的活性。
Acta Pharmacol Sin. 2000 Aug;21(8):753-8.

引用本文的文献

1
Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study.淋巴瘤患儿、青少年及青年中CYP3A4、CYP2C19和CYP2D6的表型转换:PEGASUS研究的原理与设计
Clin Transl Sci. 2025 Apr;18(4):e70209. doi: 10.1111/cts.70209.
2
Leveraging Omeprazole PBPK/PD Modeling to Inform Drug-Drug Interactions and Specific Recommendations for Pediatric Labeling.利用奥美拉唑药代动力学/药效学(PBPK/PD)模型来指导药物相互作用及儿科标签的具体建议。
Pharmaceutics. 2025 Mar 14;17(3):373. doi: 10.3390/pharmaceutics17030373.
3
Improving CYP2C19 phenotyping using stereoselective omeprazole and 5-hydroxy-omeprazole metabolic ratios.
使用立体选择性奥美拉唑和5-羟基奥美拉唑代谢率改善CYP2C19表型分析
Basic Clin Pharmacol Toxicol. 2024 Dec;135(6):755-766. doi: 10.1111/bcpt.14095. Epub 2024 Oct 9.
4
Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour.实施基于 CPIC-CYP2C19-PPI 剂量指南的药物基因组学检测,优化质子泵抑制剂在印度人群中的应用:当务之急。
Indian J Pharmacol. 2024 Jul 1;56(4):277-284. doi: 10.4103/ijp.ijp_198_24. Epub 2024 Sep 10.
5
Impact of obesity and roux-en-Y gastric bypass on the pharmacokinetics of (R)- and (S)-omeprazole and intragastric pH.肥胖和 Roux-en-Y 胃旁路手术对(R)-和(S)-奥美拉唑药代动力学和胃内 pH 值的影响。
CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1528-1541. doi: 10.1002/psp4.13189. Epub 2024 Jun 24.
6
Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism.通过细胞色素P450 3A4介导的代谢,阿瑞匹坦与伏立康唑之间存在冲突性药物相互作用的潜在机制。
Yonago Acta Med. 2024 Jan 24;67(1):31-40. doi: 10.33160/yam.2024.02.004. eCollection 2024 Feb.
7
Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions.20毫克埃索美拉唑镁肠溶片在健康中国受试者空腹和进食条件下的药代动力学及生物等效性研究
Front Pharmacol. 2023 Apr 28;14:1169103. doi: 10.3389/fphar.2023.1169103. eCollection 2023.
8
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.预测非酒精性脂肪性肝炎患者药物药代动力学的改变及药物不良反应风险
Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018. Epub 2022 Aug 28.
9
Assessing the Potential of Untargeted SWATH Mass Spectrometry-Based Metabolomics to Differentiate Closely Related Exposures in Observational Studies.评估基于非靶向SWATH质谱的代谢组学在观察性研究中区分密切相关暴露因素的潜力。
Metabolites. 2022 Oct 4;12(10):942. doi: 10.3390/metabo12100942.
10
Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy.基于多病用药患者药物-药物-基因相互作用数据的处方建议
Pharmgenomics Pers Med. 2022 Aug 18;15:765-773. doi: 10.2147/PGPM.S368606. eCollection 2022.